Rooftop solar photovoltaics currently account for 40% of the global solar photovoltaics installed capacity and one-fourth of the total renewable capacity additions in 2018. Yet, only limited information is available on its global potential and associated costs at a high spatiotemporal resolution. Here, we present a high-resolution global assessment of rooftop solar photovoltaics potential using big data, machine learning and geospatial analysis. We analyse 130 million km2 of global land surface area to demarcate 0.2 million km2 of rooftop area, which together represent 27 PWh yr−1 of electricity generation potential for costs between 40–280 $ MWh−1. Out of this, 10 PWh yr−1 can be realised below 100 $ MWh−1. The global potential is predominantly spread between Asia (47%), North America (20%) and Europe (13%). The cost of attaining the potential is lowest in India (66 $ MWh−1) and China (68 $ MWh−1), with USA (238 $ MWh−1) and UK (251 $ MWh−1) representing some of the costliest countries.

No abstract

No abstract

ObjectivesPeople who inject drugs (PWID) experience a high burden of injection drug use-related infectious disease and challenges in accessing adequate care. This study sought to identify programmes and services in Canada addressing the prevention and management of infectious disease in PWID.DesignThis study employed a systematic integrative review methodology. Electronic databases (PubMed, CINAHL and Web of Science Core Collection) and relevant websites were searched for literature published between 2008 and 2019 (last search date was 6 June 2019). Eligible articles and documents were required to address injection or intravenous drug use and health programmes or services relating to the prevention or management of infectious diseases in Canada.ResultsThis study identified 1607 unique articles and 97 were included in this study. The health programmes and services identified included testing and management of HIV and hepatitis C virus (n=27), supervised injection facilities (n=19), medication treatment for opioid use disorder (n=12), integrated infectious disease and addiction programmes (n=10), needle exchange programmes (n=9), harm reduction strategies broadly (n=6), mobile care initiatives (n=5), peer-delivered services (n=3), management of IDU-related bacterial infections (n=2) and others (n=4). Key implications for policy, practice and future research were identified based on the results of the included studies, which include addressing individual and systemic factors that impede care, furthering evaluation of programmes and the need to provide comprehensive care to PWID, involving medical care, social support and harm reduction.ConclusionsThese results demonstrate the need for expanded services across a variety of settings and populations. Our study emphasises the importance of addressing social and structural factors that impede infectious disease care for PWID. Further research is needed to improve evaluation of health programmes and services and contextual factors surrounding accessing services or returning to care.PROSPERO registration numberCRD42020142947.